Sugi Predict

Sugi Predict / Compounds / SCHEMBL807362

SCHEMBL807362

SCHEMBL807362

c1csc(CN2CCCCC2)n1

nearest known ligand 0.58

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ ALOX15 P16050 2/20 0.58
▸ TSHR P16473 5/20 0.56
▸ ALDH1A1 P00352 4/20 0.56
▸ CYP2C9 P11712 3/20 0.56
▸ CYP2D6 P10635 8/20 0.51
▸ CYP3A4 P08684 8/20 0.50
▸ CYP2C19 P33261 5/20 0.50
▸ MAPK1 P28482 2/20 0.50
▸ LTA4H P09960 1/20 0.49
▸ USP2 O75604 2/20 0.48
▸ CYP1A2 P05177 2/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4487346 0.98 ALOX15 (0.59) ALOX15TSHRALDH1A1CYP2C9CYP2D6
SCHEMBL30341042 0.89 ALOX15 (0.55) ALOX15TSHRALDH1A1CYP2C9CYP2D6
SCHEMBL13940681 0.84 ALOX15 (0.51) ALOX15TSHRALDH1A1CYP2C9CYP2D6
SCHEMBL16221501 0.84 ALOX15 (0.51) ALOX15TSHRALDH1A1CYP2C9CYP2D6
SCHEMBL6482630 0.83 ALOX15 (0.56) ALOX15TSHRALDH1A1CYP2C9CYP2D6
SCHEMBL14338850 0.83 ALOX15 (0.56) ALOX15TSHRALDH1A1CYP2C9CYP2D6
SCHEMBL211751 0.81 ALOX15 (0.72) ALOX15TSHRALDH1A1CYP2C9CYP2D6
SCHEMBL4914558 0.81 ALOX15 (0.72) ALOX15TSHRALDH1A1CYP2C9CYP2D6
SCHEMBL952226 0.81 ALOX15 (0.55) ALOX15TSHRALDH1A1CYP2C9CYP2D6
SCHEMBL6218968 0.80 ALOX15 (0.54) ALOX15TSHRALDH1A1CYP2C9CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11787785-B2 Pyrazolopyridine derivatives and uses thereof NOVARTIS AG (CH) 2023-10-17 — — US claimed
US-20230108325-A1 Pyrazolopyridine Derivatives and Uses thereof NOVARTIS AG (CH) 2023-04-06 — — US claimed
US-20240245670-A1 DOSING REGIMEN AND PHARMACEUTICAL COMBINATION COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES NOVARTIS AG (CH) 2024-07-25 — — US disclosed
US-11787785-B2 Pyrazolopyridine derivatives and uses thereof NOVARTIS AG (CH) 2023-10-17 — — US disclosed
US-20230108325-A1 Pyrazolopyridine Derivatives and Uses thereof NOVARTIS AG (CH) 2023-04-06 — — US disclosed
CN-106008322-B sulfonamide derivatives as BC L-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases ABBVIE 公司 2018-09-04 — — CN disclosed
CN-107567445-A It can be used as 2 phenyl 3H imidazos [4,5 B] pyridine derivates of mammal EGFR-TK ROR1 activities inhibitor 坎塞拉有限公司 2018-01-09 — — CN disclosed
EP-2615916-B1 FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS MERCK SHARP & DOHME (US) 2017-01-04 — — EP disclosed
EP-1831207-B1 AMINOPYRIMIDINE COMPOUNDS AS PLK INHIBITORS AMGEN INC (US) 2012-11-14 — — EP disclosed
WO-2012036997-A1 FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS SCHERING CORPORATION (US) 2012-03-22 — — WO disclosed
WO-2011163330-A1 NOVEL HETEROCYCLIC COMPOUNDS AS ERK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2011-12-29 — — WO disclosed
EP-2300475-A1 DIAZACARBAZOLES AND METHODS OF USE Genentech, Inc. (US) 2011-03-30 — — EP disclosed
US-7858785-B2 Aminopyrimidine compounds and methods of use AMGEN INC. (US) 2010-12-28 — — US disclosed
US-7786132-B2 Aminopyrimidine compounds and methods of use AMGEN INC. (US) 2010-08-31 — — US disclosed
US-20100010014-A1 AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2010-01-14 — — US disclosed
WO-2009151598-A1 DIAZACARBAZOLES AND METHODS OF USE GENENTECH, INC. (US) 2009-12-17 — — WO disclosed
CN-101115749-A Aminopyrimidine compounds and methods of use AMGEN INC (US) 2008-01-30 — — CN disclosed
EP-1831207-A1 AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE Amgen Inc. (US) 2007-09-12 — — EP disclosed
US-20070185133-A1 Aminopyrimidine compounds and methods of use AMGEN, INC. (US) 2007-08-09 — — US disclosed
WO-2006066172-A1 AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE AMGEN, INC. (US) 2006-06-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11787785-B2 Pyrazolopyridine derivatives and uses thereof HBZ, ZFX, WIZ ALOX15 3381/4885TSHR 4155/4885ALDH1A1 1243/4885
US-20240245670-A1 DOSING REGIMEN AND PHARMACEUTICAL COMBINATION COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES IKZF1, IKZF2, IKZF3 ALOX15 3627/4885TSHR 4128/4885ALDH1A1 2942/4885
US-20100010014-A1 AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE PLK1, TYMP, TK2 ALOX15 1377/4885TSHR 4700/4885ALDH1A1 1565/4885
US-20070185133-A1 Aminopyrimidine compounds and methods of use PLK1, TYMP, TK2 ALOX15 1377/4885TSHR 4700/4885ALDH1A1 1565/4885
US-20230108325-A1 Pyrazolopyridine Derivatives and Uses thereof HBZ, ZFX, WIZ ALOX15 3381/4885TSHR 4155/4885ALDH1A1 1243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.